Search results for "AGENTS"

showing 10 items of 7330 documents

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management…

2020

Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infect…

medicine.medical_specialtyAllergySettore MED/12 - GASTROENTEROLOGIAallergicPenicillinsGastroenterologyHelicobacter InfectionsDrug Hypersensitivity03 medical and health sciences0302 clinical medicineLevofloxacinMetronidazoleClarithromycinInternal medicinebismuthmedicineHumansProspective StudiesRegistriesAdverse effectlevofloxacinbiologyHelicobacter pyloribusiness.industrySettore MED/09 - MEDICINA INTERNAallergic ; allergy ; bismuth ; clarithromycin ; Helicobacter pylori ; levofloxacin ; penicillinGastroenterologyProton Pump InhibitorsGeneral MedicineTetracyclineHelicobacter pyloribiology.organism_classificationmedicine.diseaseallergyclarithromycinAnti-Bacterial Agents3. Good healthPenicillinMetronidazoleRegimenInfectious Diseasespenicillin030220 oncology & carcinogenesisDrug Therapy Combination030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct

Supportive care of the older cancer patient

2003

Aging is associated with decreased functional reserve of multiple organ systems and with changes in the pharmacokinetics and pharmacodinamics of drugs. Older individuals express enhanced susceptibility to the complications of cytotoxic chemotherapy, especially to myleotoxicity, mucositis, cardiotoxicity and neurotoxicity. The management of older individuals with chemotherapy involves then prevention of these complications. General precautions include proper patient selection, based on the comprehensive geriatric assessment (CGA), dose adjustment for agents that are renally excreted to the patient creatinine clearance and maintenance of hemoglobin levelsor =12 g/dl. Filgrastim and pegfilgras…

medicine.medical_specialtyAnemiaAntineoplastic AgentsColony-Stimulating FactorsNeoplasmsHumansMedicineRisk factorDisease management (health)Intensive care medicineAgedMyelopoiesisStomatitisbusiness.industryIncidence (epidemiology)Age FactorsMouth MucosaDisease ManagementCancerHematologymedicine.diseaseMalnutritionOncologyToxicityDeliriummedicine.symptombusinessCritical Reviews in Oncology/Hematology
researchProduct

Systemic chemotherapy in elderly patients with locally advanced and/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and …

2003

Abstract A review of the incidence and management of anemia in elderly patients with head and neck carcinoma treated with systemic chemotherapy. The role of recombinant human erythropoietin in preventing or correcting chemotherapy-related anemia has been focused. Data concerning the prospective use of recombinant human erythropoietin (rhEpo) in a series of unfit elderly patients (EPs) treated with carboplatin plus 5-fluorouracil. Patients were randomly assigned to receive subcutaneous rhEpo 10,000 U three times per week (TIW) (23 elderly patients) or no treatment (22 control patients). Recombinant hEpo was able to prevent anemia and to reduce transfusional requirements in treated patients a…

medicine.medical_specialtyAnemiamedicine.medical_treatmentAntineoplastic AgentsGastroenterologychemistry.chemical_compoundQuality of lifehemic and lymphatic diseasesInternal medicinemedicineHumansErythropoietinAgedChemotherapybusiness.industryIncidenceIncidence (epidemiology)AnemiaHematologymedicine.diseaseRecombinant ProteinsCarboplatinSurgeryOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsErythropoietinCarcinoma Squamous CellbusinessComplicationmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

2012

Zoledronic acid (ZOL) is the most potent nitrogen-containing bisphosphonate (N-BPs) that strongly binds to bone mineral and acts as a powerful inhibitor of bone resorption, already clinically available for the treatment of patients with osteolytic metastases. Recent data also suggest that ZOL, used in breast cancer, may provide more than just supportive care modifying the course of the disease, though the possible molecular mechanism of action is still unclear. As breast cancer is one of the primary tumours with high propensity to metastasize to the bone, we investigated, for the first time, differential gene expression profile on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells tre…

medicine.medical_specialtyAngiogenesismedicine.medical_treatmentBlotting WesternAngiogenesis InhibitorsAntineoplastic AgentsBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionZoledronic AcidZOL FN1 TGF-b1 THBS-1 invasion breast cancerBone resorptionThrombospondin 1Transforming Growth Factor beta1breast cancerBreast cancerTGF-β1Internal medicineThrombospondin 1medicineHumansBone ResorptionCell ProliferationMatrigelDiphosphonatesFN1Gene Expression ProfilingImidazolesCancerOriginal ArticlesCell BiologyZOLBisphosphonateMicroarray Analysisinvasionmedicine.diseaseFibronectinsUp-RegulationGene Expression Regulation NeoplasticEndocrinologyZoledronic acidTHBS-1MCF-7 CellsCancer researchMolecular MedicineFemalemedicine.drug
researchProduct

Long-term care of AIDS and non-communicable diseases.

2011

medicine.medical_specialtyAnti-HIV AgentsDeveloping countryMedically Underserved AreaUterine Cervical NeoplasmsZambiaComorbidityHealth servicesAcquired immunodeficiency syndrome (AIDS)Cause of DeathMedicineHumansMass ScreeningIntensive care medicineDeveloping CountriesAcquired Immunodeficiency SyndromeHealth Services Needs and Demandbusiness.industryCancerGeneral Medicinemedicine.diseaseLong-term careFamily medicineChronic DiseaseFeasibility StudiesFemalebusinessLancet (London, England)
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Non-wild-type cryptococcosis in a child with multivisceral organ transplant who owned bird pets.

2020

Cryptococcosis is the third most common invasive fungal infection in solid-organ transplant recipients, although it is rarely reported in transplanted children. It typically appears as a late-onset infection with central nervous system or pulmonary involvement. We present a case of cryptococcosis caused by a non-wild strain in a 10-year-old child who owned two pet birds, and review the existent literature.

medicine.medical_specialtyAntifungal AgentsCentral nervous systemDrug resistance030230 surgeryOrgan transplantationBirds03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansChildCryptococcus neoformansTransplantationNon wild typebiologybusiness.industryCryptococcosisOrgan TransplantationPetsbiology.organism_classificationmedicine.diseaseInfectious Diseasesmedicine.anatomical_structureImmunologyCryptococcosisCryptococcus neoformans030211 gastroenterology & hepatologySolid organ transplantationbusinessTransplant infectious disease : an official journal of the Transplantation SocietyREFERENCES
researchProduct

Current Concepts in Therapy of Chronic Rhinosinusitis and Nasal Polyposis

2004

The exact pathophysiological mechanisms leading to chronic rhinosinusitis (CRS) still to a large extent remain obscure. However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators. Endonasal sinus surgery has evolved to be the treatment of choice in CRS and nasal polyposis in all cases where conservative treatment has failed or resulted in only a partial or temporary relief. Today, state of the art in surgical technique includes the ability to combine microscopic and endoscopic procedures. Regardless of technical advances like powered instrumentatio…

medicine.medical_specialtyAntifungal AgentsChronic rhinosinusitisNasal PolypsPostoperative ComplicationsEosinophiliaParanasal Sinusesotorhinolaryngologic diseasesmedicineHumansEosinophiliaNasal polypsSinusitisSinusitisRhinitisAspirinmedicine.diagnostic_testbusiness.industryEndoscopyrespiratory systemmedicine.diseaseAnti-Bacterial AgentsEndoscopySurgeryConservative treatmentTreatment OutcomeSurgery Computer-AssistedOtorhinolaryngologyChronic DiseaseHistamine H1 AntagonistsEtiologySteroidsASPIRIN INTOLERANCEmedicine.symptombusinessORL
researchProduct

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital se…

2007

As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable…

medicine.medical_specialtyAntifungal AgentsLiposomal amphotericin Blaw.inventionNephrotoxicitychemistry.chemical_compoundEchinocandinsLipopeptidesRandomized controlled trialDouble-Blind MethodlawCaspofunginBottom-up studyAmphotericin BInternal medicineAmphotericin BGermanymedicineHumansLongitudinal StudiesProspective StudiesProspective cohort studyIntensive care medicineNephrotoxicitybusiness.industryGeneral MedicineHematologybacterial infections and mycosesConfidence intervalEconomic evaluationchemistryMycosesLiposomesNumber needed to treatCosts and Cost AnalysisObservational studyOriginal ArticleCaspofunginbusinessmedicine.drugAnnals of Hematology
researchProduct

Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B

1996

An important determinant of nephrotoxicity, which is the major complication of long-term amphotericin B treatment, is dysfunction of distal tubular epithelial cells. The underlying cause for this rather selective damage to the cells is unknown. In the present investigation, it was shown that kidney epithelial cells were initially damaged by amphotericin B at concentrations of 2.5 to 10 micrograms/ml, as demonstrable by a dramatic drop in cellular K+ levels. Cells could recover from the initial toxic action of the polyene if they were kept in medium of neutral pH, and cellular K+ levels returned to normal after 6 h. However, the recovery mechanisms failed at lower pHs of 5.6 to 6.0. At low p…

medicine.medical_specialtyAntifungal AgentsLumen (anatomy)PharmacologyBiologyEpitheliumCell LineNephrotoxicitychemistry.chemical_compoundAdenosine TriphosphateAmphotericin BInternal medicineAmphotericin BLactate dehydrogenasemedicineAnimalsPharmacology (medical)Kidney Tubules DistalPharmacologyKidneyL-Lactate DehydrogenaseHydrogen-Ion ConcentrationMacaca mulattaIn vitroEpitheliumInfectious Diseasesmedicine.anatomical_structureEndocrinologychemistryToxicityPotassiumResearch Articlemedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct